In Silico Design of a Novel Multi-Epitope Peptide Vaccine Against Hepatocellular Carcinoma

(E-pub Ahead of Print)

Author(s): Fatemeh Motamedi Dehbarez, Navid Nezafat, Shirin Mahmoodi*.

Journal Name: Letters in Drug Design & Discovery

Become EABM
Become Reviewer

Abstract:

Background: Hepatocellular carcinoma (HCC) is a prevalent cancer in the world. As yet, there is no medication for complete treatment of HCC. Objective: There is a critical need to search for an innovative therapy for HCC. Recently, multi-epitope vaccines have introduced as an effective immunotherapy approach against HCC.

Methods: In this research, several immunoinformatics methods were applied to create an original multi-epitope vaccine against HCC consisting of CD8+ cytolytic T lymphocytes (CTLs) epitopes selected from α- fetoprotein (AFP), glypican-3 (GPC3), aspartyl-β-hydroxylase (ASPH); CD4+ helper T lymphocytes (HTLs) epitopes from tetanus toxin fragment C (TTFC), and finally, two tandem repeats of HSP70407-426 were which stimulate strong innate and adaptive immune responses. All the mentioned parts were connected together by relevant linkers.

Results: According to physicochemical, structural, and immunological results, the designed vaccine is stable, non-allergen, antigen; it also has a high-quality 3D structure, and numerous linear and conformational B cell epitopes, whereby this vaccine may stimulate efficient humoral immunity.

Conclusion: Center on the collected results, the designed vaccine potentially can induce cellular and humoral immune responses in HCC cases; nonetheless, the efficiency of vaccine must be approved within in vitro and in vivo immunological analyzes.

Keywords: Hepatocellular carcinoma, immunoinformatics, multi-epitope vaccine, adjuvant, immunotherapy, linker

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1570180817999200502030038
Price: $95